Key result
Quercetin improves LVEF and reduces myocardial fibrosis in diabetic cardiomyopathy models.
Why the study?
The biological mechanisms underlying the protective effects of quercetin in diabetic cardiomyopathy are unclear.
p-value: p=<0.05
Quercetin has multiple protective effects against cardiometabolic diseases, but the biological mechanisms underlying the benefits in diabetic cardiomyopathy (DCM) are unclear. A mouse DCM model was established by high-fat diet (HFD, 8 months) combined with streptozotocin injection (at the mid-feeding), and quercetin (100 mg per kg per day) was administrated orally after streptozotocin. Our major results indicated that the cardiac ejection fraction and fractional shortening, mRNA levels of Collagen I and CTGF, and the protein expression levels of NLRP3, caspase-1, IL-1β, and IL-18 were reduced (P < 0.05) in DCM mice in response to quercetin intervention. Serum metabolomic analyses identified glycerophospholipid metabolism as the main pathway implicated in the cardiac benefits of quercetin in DCM. Such findings showed that quercetin may ameliorate cardiac dysfunction and myocardial fibrosis via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in DCM.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2022) studied Diabetic cardiomyopathy (DCM). Quercetin vs. Untreated DCM mice (implied) was evaluated on Cardiac ejection fraction, fractional shortening, mRNA levels of Collagen I and CTGF, and protein expression levels of NLRP3, caspase-1, IL-1β, and IL-18 (p=<0.05). Quercetin administration significantly improved cardiac ejection fraction and fractional shortening while reducing inflammatory markers and myocardial fibrosis in a diabetic cardiomyopathy mouse model (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: